Vol. 20/No. 20

Atezolizumab (Tecentriq) plus bevacizumab (Avastin) resulted in clinically meaningful and durable objective responses as first-line therapy for patients with previously untreated, unresectable disease.

Immunotherapies designed to exploit the host immune system to specifically target cancer cells exploded onto the oncology scene in the mid-1980s, when the first such agents started to show success in melanoma and renal cell carcinoma.

Armando E. Giuliano, MD, a 2018 OncLive Giants of Cancer Care® award winner in Surgical Oncology, disrupted the treatment landscape for early breast cancer when he introduced sentinel lymph node biopsy. The result led to improved quality of life and reduced the need for radical breast cancer procedures for many patients.

Using dual checkpoint inhibitors in patients with hepatocellular carcinoma is demonstrating activity with a manageable safety profile in both second-line and perioperative settings.

A new set of recommendations for the treatment of small bowel adenocarcinoma, a relatively rare type cancer of the gastrointestinal tract, have been created by the National Comprehensive Cancer Network. The guidelines are the first in the United States and second in the world to recommend treatments specific to the malignancy, which is often diagnosed at advanced stages.

Findings from a national survey show that vaping is not only more common but also more favorably perceived among younger age groups than older adults.

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

In an interview with OncologyLive®, Scott Gottlieb, MD, shared his insights on developments in the oncology arena.

Jeff Sharman, MD, discusses the current approval and potential future roles for polatuzumab vedotin-piiq (Polivy) in diffuse large B-cell lymphoma.

New treatment approaches for patients with relapsed or refractory advanced breast cancer are making their way into clinical practice or are on the horizon.

In the phase II CLOVER-1 trial, investigators are evaluating whether CLR 131 will be an effective option for patients with difficult-to-treat relapsed or refractory B-cell lymphomas.

In men with oligometastatic prostate cancer, treatment with stereotactic ablative radiation led to significant improvements in progression-free survival, especially in highrisk mutation-negative patients, and confirmed the value of tests for predicting benefit from SABR, according to findings from the phase II ORIOLE trial presented at the 61st Annual Meeting of the American Society for Radiation Oncology.

The artificial intelligence system that IBM designed for oncology has demonstrated clinical utility in recent studies, generating excitement that the technology may have a role as a decision support tool.

A partnership between a healthcare system in Morristown, New Jersey, and a genomics research institute in Phoenix, Arizona, has led to the opening of a center dedicated to offering phase I cancer trials in community settings and improving access for patients with limited coverage.

Emboldened by strong evidence investigators are growing confident that localized therapy in oligometastatic disease across cancers may soon lead to a new staging system and become standard of care.

Even if a disease is diagnosed as “incurable,” or progression to a state of incurability subsequently develops, the time between diagnosis and death is being prolonged and the quality of life improved with novel oncologic interventions, such that continued therapeutic efforts are justified.